Safeguarding Australia: Navigating Medicine Shortages Amid Global Disruptions

Australia's medicine supply chain is currently robust enough to manage short-term disruptions despite ongoing global conflicts affecting supply routes. However, prolonged instability could increase the risk of shortages, especially for non-PBS medicines. Strategic stock requirements and temporary importations help mitigate risks, but increasing local production could enhance resilience.

Amid rising global tensions disrupting supply routes, Australia remains poised to manage its medicine supply chain effectively. With systems in place since July 2023 under the Pharmaceutical Benefits Scheme, manufacturers are required to hold a reserve stock to cushion against supply shortages.

While most common medicines are safe from immediate disruption, those not listed on the PBS, such as newer medicines on private prescriptions, face higher risks. Ongoing medicine shortages, including ADHD medications and some antibiotics, highlight the vulnerabilities within the supply chain.

The potential for prolonged instability calls for increased local production and strategic stockholding as the country relies heavily on international sources, particularly from the US, Europe, India, and China.